• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药物代谢中的种族差异。

Ethnic differences in drug metabolism.

作者信息

Zhou H H, Liu Z Q

机构信息

Pharmacogenetics Research Institute, Hunan Medical University, Hunan, China.

出版信息

Clin Chem Lab Med. 2000 Sep;38(9):899-903. doi: 10.1515/CCLM.2000.131.

DOI:10.1515/CCLM.2000.131
PMID:11097347
Abstract

Ethnic differences in drug metabolism are well documented for a number of drugs. The molecular mechanisms responsible for ethnic differences in drug metabolism have been partly clarified because of the advances in molecular biology in recent years. Gene dosage determines the drug metabolism as demonstrated for S-mephenytoin and diazepam metabolism. Genotype analysis indicates a different frequency for the mutant alleles in different ethnic populations, which results in variations in the frequency of subjects who are homozygous for the mutant allele among the extensive metabolizers in different ethnic populations. Ethnic differences in drug metabolism may result from differences in distribution of a polymorphic trait and mutations which code for enzymes with abnormal activity which occur with altered frequency in different ethnic groups.

摘要

许多药物的药物代谢存在种族差异,这已得到充分证明。由于近年来分子生物学的进展,药物代谢种族差异的分子机制已部分得到阐明。基因剂量决定药物代谢,如S-美芬妥英和地西泮代谢所示。基因型分析表明,不同种族人群中突变等位基因的频率不同,这导致不同种族人群中广泛代谢者中突变等位基因纯合子个体的频率存在差异。药物代谢的种族差异可能源于多态性特征分布的差异以及编码活性异常酶的突变,这些突变在不同种族群体中的发生频率有所改变。

相似文献

1
Ethnic differences in drug metabolism.药物代谢中的种族差异。
Clin Chem Lab Med. 2000 Sep;38(9):899-903. doi: 10.1515/CCLM.2000.131.
2
Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.多态性药物氧化的地理/种族差异。细胞色素P450(CYP)2D6和2C19的现有知识状况。
Clin Pharmacokinet. 1995 Sep;29(3):192-209. doi: 10.2165/00003088-199529030-00005.
3
Identifying drugs needing pharmacogenetic monitoring in a Korean hospital.在一家韩国医院中识别需要进行药物基因组学监测的药物。
Am J Health Syst Pharm. 2007 Jan 15;64(2):166-75. doi: 10.2146/ajhp050490.
4
Molecular mechanisms of genetic polymorphisms of drug metabolism.药物代谢遗传多态性的分子机制
Annu Rev Pharmacol Toxicol. 1997;37:269-96. doi: 10.1146/annurev.pharmtox.37.1.269.
5
Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele.中国汉族和白族人群中影响S-美芬妥英代谢表型的CYP2C19基因多态性发生率差异及一种新的罕见CYP2C19突变等位基因的鉴定
J Pharmacol Exp Ther. 1997 Apr;281(1):604-9.
6
Individual and ethnic differences in CYP2C19 activity in Chinese populations.
Acta Pharmacol Sin. 2000 Mar;21(3):193-9.
7
Brief review of polymorphic drug-metabolizing enzymes in Japanese populations: development of a higher-throughput genotyping method and proposed applications.
Drug Metab Lett. 2007 Apr;1(2):137-42. doi: 10.2174/187231207780363679.
8
S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians.埃塞俄比亚人中S-美芬妥因羟基化表型与CYP2C19基因型
Pharmacogenetics. 1996 Dec;6(6):521-6. doi: 10.1097/00008571-199612000-00005.
9
Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.鉴定一种导致日本人中(S)-美芬妥因代谢多态性的新基因缺陷。
Mol Pharmacol. 1994 Oct;46(4):594-8.
10
CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase.
Clin Chim Acta. 2001 Nov;313(1-2):203-8. doi: 10.1016/s0009-8981(01)00696-9.

引用本文的文献

1
Multiple Sclerosis in People of Diverse Racial and Ethnic Backgrounds: Presentation, Disease Course, and Interactions with Disease-Modifying Therapy.不同种族和族裔背景人群中的多发性硬化症:临床表现、疾病进程以及与疾病修正治疗的相互作用
CNS Drugs. 2025 Jul 18. doi: 10.1007/s40263-025-01205-4.
2
Ethnic Aspects of Valproic Acid P-Oxidation.丙戊酸P-氧化的种族因素
Biomedicines. 2024 May 8;12(5):1036. doi: 10.3390/biomedicines12051036.
3
Pharmacogenetics in early drug development for non-alcoholic steatohepatitis: missed chances and future opportunities.
非酒精性脂肪性肝炎早期药物研发中的药物遗传学:错失的机会与未来的机遇
Arch Toxicol. 2023 Jun;97(6):1825-1827. doi: 10.1007/s00204-023-03498-0. Epub 2023 May 6.
4
Multi-center Performance Evaluations of Tacrolimus and Cyclosporine Electrochemiluminescence Immunoassays in the Asia-Pacific Region.亚太地区他克莫司和环孢素电化学发光免疫分析的多中心性能评估。
Ann Lab Med. 2018 Mar;38(2):85-94. doi: 10.3343/alm.2018.38.2.85.
5
Bioequivalence and rapid absorption of zolmitriptan nasal spray compared with oral tablets in healthy Japanese subjects.健康的日本受试者中,佐米曲坦鼻喷雾剂与口服片剂的生物等效性和快速吸收。
Clin Drug Investig. 2005;25(3):199-208. doi: 10.2165/00044011-200525030-00006.
6
Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment.药物反应中的种族和民族差异:走向个体化药物治疗
J Natl Med Assoc. 2002 Oct;94(10 Suppl):1-26.